[在缺血性中风患者中早期的抗血栓保护]
E A Shirokov1, N V Lomakin1,2, L I Buryachkovskaya3
1Russian Medical Academy of Continuing Professional Education, Moscow, Russia.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
|September 3, 2025
概括
早期的抗血小板治疗为急性缺血性中风患者提供了安全有效的替代方案,特别是当再输血治疗不可行时. 这种方法在中风发作后不久提供了至关重要的抗血栓保护.
科学领域:
- 神经学
- 心血管医学
- 血栓形成研究
背景情况:
- 与动脉样硬化相关的缺血性中风是一种主要的心血管并发症.
- 目前的再输血疗法 (血栓溶解,内血管) 是有效的,但在4. 5小时的窗口内只能达到10%的患者.
- 在狭窄的治疗窗口之外的患者有有限的治疗选择.
研究的目的:
- 探索早期抗血小板治疗作为急性缺血性中风的替代治疗方法.
- 评估立即使用抗血小板剂的疗效和安全性.
- 讨论在缺血性中风患者中早期抗血栓性脑保护的方法.
主要方法:
- 对急性缺血性中风的抗血小板治疗最近的临床研究的综述.
- 对无法再输血的患者的治疗策略的分析.
- 基于中风严重性的抗血栓保护方法的讨论.
主要成果:
- 最近的研究表明,立即抗血小板治疗具有很高的疗效和安全性.
- 早期使用抗血小板药物对于未接受血栓溶解或手术的患者来说是可行的替代方案.
- 在中风开始后,可以立即启动有效的抗血栓保护.
结论:
- 立即的抗血小板治疗是急性缺血性中风的有希望的策略.
- 这种方法扩大了传统的再输血窗口之外的治疗选择.
- 早期干预可以改善中风患者的抗血栓保护.
相关概念视频
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
The Blood-brain Barrier
48.6K
Overview
48.6K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
889
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
889
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
644
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
644


